This summary is generated by an algorithm. If you find any mistakes, let us know.

North America Pharmaceuticals

Amplicore Closes $4M Seed Funding

– Amplicore from Cincinnati develops minimally invasive therapeutic solutions for musculoskeletal diseases.
– The company closed its $4m seed round of funding.
– The round was led by Photon Fund, with participation from Industrial Technology Investment Corporation, Berkeley Catalyst Fund, and SVE Capital.
– The new investment will be used to complete the preclinical development of the company’s two leading products, AM3101 and AM1101, and position itself for the next round of financing.

North America Pharmaceuticals

Tavotek Biotherapeutics Snares $20M in Series A

– Tavotek Biotherapeutics from Lower Gwynedd, Pennsylvania, has raised over $20M in financing in the preceding two months.
YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Capital.
– Series A2 financing was jointly invested by GF Xinde, CTS Capital, and Lanhu Capital.

North America Pharmaceuticals

Minority Owned Cannabis Company, TheraTrue, Inc., Announces New CEO Victor Mancebo, $50 Million in Funding, and Applies in Georgia and Virginia

– Theratrue, Inc. announced the addition of cannabis industry veteran Victor E. Mancebo as the company’s Chief Executive Officer.
– In addition, Theratrue has received $50m in funding commitments and submitted medical cannabis license applications in Georgia and Virginia.
– These applications mark the first major actions of Theratrue Inc. in the medical cannabis industry.
– Theratrue is committed to using extensive research and cutting-edge technology to provide vertically integrated production facilities designed to safely deliver medical grade cannabis products to patients in Georgia and Virginia.
– Victor E. Mancebo has joined Theratrue Inc. as CEO.
– Mr. Mancebo also serves as President and Chief Operating Officer of Theratrue Georgia LLC and Theratrue Virginia LLC.

Asia Pharmaceuticals

YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercialization

– YishengBio announced that it has raised US$130m in Series B funding.
– The round was co-led by Oceanpine and OrbiMed.
– The company’s institutional investors include: OrbiMed, Oceanpine, EightRoad, F-Prime Capital, 3W Capital, Hillhouse Capital, Adjuvant Capital, MSA Capital, AIHC, Epiphron Capital, Superstring Capital, Haitong International, etc.
– The company is engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using novel PIKA® immunomodulating technology.
– The company operates in China, USA, and Singapore with over 500 employees.
– YSJA™ rabies vaccine is the first alum-free lyophilized rabies vaccine launched in China.

North America Pharmaceuticals

Teon Therapeutics Completes $30 Million Series A Financing

– Teon Therapeutics completed a $30m Series A financing.
– The financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments, and former Gilead senior executives.
– All existing investors also participated in the financing round including Northern Light Venture Capital, Kaitai Capital and Oriental Fortune Capital.
– The funds will be used to advance the company’s lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company’s pipeline.

Crunchbase icon

Content report

The following text will be sent to our editors: